Current Status of the Effectiveness of Infliximab with Crohn's disease-A prospective observational study of serum Infliximab consentrations-

Current Status of the Effectiveness of Infliximab with Crohn's disease-A prospective observational study of serum Infliximab consentrations- - Current Status of the Effectiveness of Infliximab with Crohn's disease-A prospective observational study of serum Infliximab consentrations-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028343

Enrollment

Registered

2017-07-23

Start date

2013-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Crohn's disease active stage in Kitasato University Hospital over 16 years old

Exclusion criteria

Exclusion criteria: Patients enrolled in other clinical trial pregnancy past history: cancer, malignancy serious infection tuberculosis allergy to medicine multiple sclerosis heart fairuler

Design outcomes

Primary

Measure	Time frame
improvement rates 54 weeks after starting treatment with infliximab	—

Secondary

Measure	Time frame
remission and improvement rates 14, 54 and 102 weeks after starting treatment with infliximab serum infliximab concentrations and ATI rates at these times correlations of serum infliximab concentrations with disease severity and the treatment response The rate of continuing treatment with infliximab side effect	—

Countries

Japan

Contacts

Public ContactKaoru Yokoyama

Kitasato University School of Medicine Gastroenterology

kaoru.y@kitasato-u.ac.jp042-778-8111

Outcome results